Refractory Morvan syndrome responsive to rituximab: a case report and review of the literature.
CASPR2
LGI1
Morvan syndrome
Rituximab
Journal
Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
08
02
2022
revised:
30
05
2022
accepted:
01
06
2022
pubmed:
18
6
2022
medline:
19
8
2022
entrez:
17
6
2022
Statut:
ppublish
Résumé
Morvan Syndrome (MoS) is an autoimmune disorder characterized by peripheral nerve hyperexcitability, autonomic dysfunction, and encephalopathy. We describe the case of a man with a history of thymoma diagnosed with a paraneoplastic MoS with a severe painful neuropathy refractory to immunoglobulins and steroids who had a dramatic and lasting response following treatment with rituximab. We also reviewed the clinical features, comorbidities, laboratory findings, treatment responses, relapses, and long-term outcomes of all published cases of MoS treated with rituximab. This drug appears promising for the treatment of patients with MoS who failed first line therapy with immunoglobulins and steroids.
Identifiants
pubmed: 35715317
pii: S0960-8966(22)00166-3
doi: 10.1016/j.nmd.2022.06.001
pii:
doi:
Substances chimiques
Autoantibodies
0
Steroids
0
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
682-686Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.